drugset / Trial / NCT05604287
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
Phase 1
Terminated
67 enrolled
IlDong Pharmaceutical Co Ltd
Parexel · collabYUNOVIA CO.,LTD. · collab
RandomizedSequentialDouble-blindTreatment
Summary
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
Timeline
- Start
- 2022-10-10
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
Outcome
Outcome not reported
Stopped: “Sponsor have decided to cancel the trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ID119031166M | Unknown | — | Oral |
Indications
No indication recorded.